Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
TSC2
REST API REST API
Homo sapiens
TSC2 is differentially expressed in 223 experiments: 78 organism parts: cerebellum, salivary gland, ... (76 more);, 118 disease states: normal, prostate carcinoma, ... (116 more);, 55 cell types 235 cell lines 42 compound treatments and 64 other conditions.
Synonyms tuberin, LAM, TSC4
Orthologs Tsc2 (Rattus norvegicus)   tsc2 (Danio rerio)   TSC2 (Bos taurus)   TSC2 (Gallus gallus)   ENSCING00000007183 (Ciona intestinalis)   Tsc2 (Mus musculus)   gig (Drosophila melanogaster)   tsc2 (Xenopus laevis)   Q9XSY8_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, protein localization, protein binding, establishment of protein localization, cytoplasm, intracellular, negative regulation of cell proliferation, negative regulation of protein kinase activity, protein complex, protein import into nucleus, acute-phase response, membrane, protein homooligomerization, Golgi apparatus, cell cycle arrest, insulin-like growth factor receptor signaling pathway, insulin receptor signaling pathway, membrane raft, response to hypoxia, membrane fraction, negative regulation of Wnt receptor signaling pathway, fibroblast growth factor receptor signaling pathway, positive chemotaxis, vesicle-mediated transport, protein kinase B signaling cascade, GTPase activator activity, neuron projection, microsome, regulation of cell cycle, nucleus, heart development, protein heterodimerization activity, negative regulation of TOR signaling cascade, regulation of small GTPase mediated signal transduction, dendrite, growth cone, perinuclear region of cytoplasm, negative regulation of protein kinase B signaling cascade, protein homodimerization activity, binding, negative regulation of MAP kinase activity, cell projection organization, negative regulation of epithelial cell proliferation, signal transduction, regulation of insulin receptor signaling pathway, positive regulation of GTPase activity, negative regulation of cell size, caveola, endocytosis, neuronal cell body, TSC1-TSC2 complex, neural tube closure, cytoskeletal part, regulation of endocytosis, nerve growth factor receptor signaling pathway, protein heterooligomerization, phosphatidylinositol-mediated signaling, 14-3-3 protein binding, phosphatidylinositol 3-kinase cascade, negative regulation of phosphatidylinositol 3-kinase cascade
InterPro Term Rap_GAP, Tuberin-type_domain, Tuberin, Tuberin_N
UniProt Accession Q5HYF7, P49815, C9JWX6, C9JX95, B4DIL8, E9PGN1
Gene-Disease Assocation TUBEROUS SCLEROSIS 1; TSC1, TUBEROUS SCLEROSIS 2; TSC2, LYMPHANGIOLEIOMYOMATOSIS; LAM
Search EB-eye ENSG00000103197
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-GEOD-22541, E-MTAB-24, E-MTAB-25, ... (21 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-4717, ... (28 experiments)

Factor Value U/D Experiments
MCF-7
2
E-GEOD-20081, E-GEOD-3529
SW480
2
E-MEXP-1014, E-MTAB-37
Malme3M
1
E-MTAB-37
NCIH322
1
E-MTAB-37
MOLT-4
1
E-GEOD-96
SK-N-SH
1
E-MTAB-62
229 more value(s).


Cell type

studied in E-GEOD-3920, E-GEOD-20677, E-GEOD-13909, E-GEOD-4219, E-GEOD-13987, ... (29 experiments)

Factor Value U/D Experiments
CD8+ T cell
4
1
E-AFMX-5
chondrocyte
1
E-TABM-130
basophil
1
E-GEOD-3982
CD105+ endothelial
1
1
E-AFMX-5
erythrocyte
1
E-MEXP-583
monolayer
1
E-GEOD-4219
49 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-15960, E-GEOD-2466, E-MEXP-2280, ... (42 experiments)

Factor Value U/D Experiments
prostate carcinoma
3
E-MTAB-62, E-MEXP-2034, E-GEOD-96
lung carcinoma
2
E-MTAB-37, E-GEOD-6014
uterine fibroid
2
E-GEOD-7307, E-MTAB-62
metabolic syndrome
1
E-MTAB-62
Follicular Adenoma
1
E-MEXP-2442
inflammatory myopathy
1
E-MTAB-62
112 more value(s).


Compound treatment

studied in E-GEOD-1615, E-GEOD-6907, E-GEOD-15205, E-GEOD-697, E-GEOD-3720, ... (24 experiments)

Factor Value U/D Experiments
glutamine
2
E-MEXP-1335, E-MEXP-941
placebo
2
E-MEXP-1335, E-MEXP-1327
U0126
1
E-GEOD-697
unknown
1
E-GEOD-7307
control - keratinocyte growth factor
1
E-GEOD-7216
NaOH
1
E-MEXP-2590
36 more value(s).


Biosource provider

studied in E-GEOD-14359, E-GEOD-20559

Factor Value U/D Experiments
Fox Chase Cancer Center Biorepository
1
E-GEOD-20559
Provitro GmbH, Berlin, Germany
1
E-GEOD-14359
Charite Universitätsmedizin Berlin
1
E-GEOD-14359


BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-2191, E-GEOD-21589, ... (8 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-MEXP-2283, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-3325, E-GEOD-22541, E-TABM-147

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MEXP-563

Genotype
studied in E-TABM-1029, E-GEOD-2466, E-GEOD-22593, E-TABM-43, E-TABM-868, ... (6 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-7011, E-MEXP-2657, E-GEOD-12773, E-MEXP-1446, ... (8 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

immunoprecipitated protein
studied in E-GEOD-21918

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-2466, E-GEOD-1926, E-MEXP-2069, ... (28 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-980, E-GEOD-17400 ... (5 experiments)

Initial distant metastases
studied in E-GEOD-22541

Ki67 ihc
studied in E-GEOD-21653

Light
studied in E-GEOD-1725

Localisation of metastases
studied in E-GEOD-22541

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-AFMX-1, E-GEOD-426, E-TABM-84

Original diagnosis
studied in E-GEOD-21521

Phase
studied in E-GEOD-4888

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-19246

RNAi
studied in E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, E-MEXP-1315, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-18995

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-22152, E-GEOD-21909, E-GEOD-19246, E-GEOD-19815

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-22541, E-GEOD-6532, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.437 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM